Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 15INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Lymphoid 11Tumor-Agnostic 3Thoracic 3Breast 3Plasma cell 2Genitourinary 2Gastrointestinal 2Myeloid 1Gynecologic 1

Conditions

Myelodysplastic Syndromes 323Leukemia, Myeloid, Acute 276Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Leukemia 116Myeloproliferative Disorders 106Primary Myelofibrosis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Leukemia, Myelomonocytic, Chronic 78Polycythemia Vera 73Hematologic Neoplasms 67Multiple Myeloma 50Neoplasms 41Lymphoma, Non-Hodgkin 40Thrombocythemia, Essential 39Hematologic Diseases 38Leukemia, Lymphocytic, Chronic, B-Cell 37Recurrence 35Lymphoma 32Leukemia, Myeloid, Chronic-Phase 31Mastocytosis, Systemic 26Bone Marrow Diseases 25Leukemia, Myeloid 23Blast Crisis 23Anemia, Refractory, with Excess of Blasts 23Hodgkin Disease 21Bronchiolitis Obliterans Syndrome 16Mastocytosis 15Philadelphia Chromosome 14Leukemia, Mast-Cell 13Graft vs Host Disease 13

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm, Residual × Myeloid × Clear all
NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡